Ulysses Diversified Holding

Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.

WelbeHealth is a healthcare organization dedicated to serving frail seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company provides a comprehensive model of medical and social care, enabling elderly participants to live healthier, longer, and more independent lives. Founded by experienced physician entrepreneurs, WelbeHealth's leadership team has backgrounds in prominent payer and provider organizations. The company coordinates all aspects of care for its participants, including medical and dental services, therapy, transportation, and meal provision, ensuring a fully integrated approach to health management. By focusing on quality, compassion, and value, WelbeHealth aims to enhance the lives of vulnerable seniors in the community.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

WelbeHealth is a healthcare organization dedicated to serving frail seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company provides a comprehensive model of medical and social care, enabling elderly participants to live healthier, longer, and more independent lives. Founded by experienced physician entrepreneurs, WelbeHealth's leadership team has backgrounds in prominent payer and provider organizations. The company coordinates all aspects of care for its participants, including medical and dental services, therapy, transportation, and meal provision, ensuring a fully integrated approach to health management. By focusing on quality, compassion, and value, WelbeHealth aims to enhance the lives of vulnerable seniors in the community.